Sanofi and Translate Bio have started a phase-I clinical trial evaluating an mRNA-based investigational vaccine against seasonal influenza, the companies said on Tuesday.
The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus.
Flu seasons dominated by A/H3N2 strain circulation activity tend to be more severe, especially among those considered at risk, such as older adults and younger children, the companies added.
Antibiotic use has surged globally, leading to a rise in antibiotic resistance, especially concerning in…
Choking is a leading cause of injury and death in young children, particularly those under…
Hard Water (Khara Pani) Leading To Hair Fall Hard water is rich in minerals and…
Discover how the rise in high blood pressure during pregnancy is impacting maternal and fetal…
"Discover the transformative power of six delicious homemade drinks that can help you naturally melt…
"Transform your weight loss routine with these eight delicious fat-flushing drinks that not only hydrate…